

Selective inhibition of host cell signaling for rotavirus antivirals: PI3K/Akt/mTOR-mediated rotavirus pathogenesis

Jason Kindrachuk

Laboratory of Emerging and Re-Emerging Viruses, Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada

ARTICLE HISTORY Received 30 June 2017; Accepted 5 July 2017

KEYWORDS autophagy; cell signaling; drug repurposing; pathogenesis; rotavirus

In spite of over 40 years of basic and clinical research on rotaviruses following their discovery in 1973, rotaviruses continue to be a global health concern in children. Rotavirus, a member of the *Reoviridae* family of viruses, is the most common infectious agent underlying severe diarrheal disease in children¹ and is responsible for approximately one-third of all cases requiring hospitalization.² Rotavirus enteritis results in >500,000 deaths annually in children less than 5 y according to World Health Organization estimates.³ Although 2 licensed oral, live, attenuated rotavirus vaccines are available internationally (Rotarix and RotaTeq) >90% of rotavirus-mediated childhood fatalities occur within developing nations due to limited access to the vaccines, sanitation concerns and insufficient availability to routine healthcare services.⁴ Clinical management for acute rotavirus enteritis largely consists of oral rehydration therapy and zinc supplementation as there are no licensed antiviral therapies approved for rotavirus infections. As rotaviruses also cause severe diarrheal disease in young animals, including livestock species, they also represent a considerable threat to global livestock health with the potential for severe economic consequences. Increased clarity regarding the relation between rotavirus molecular pathogenesis and pathophysiology could help inform current patient care modalities. Further, the identification of key molecular determinants involved in the pathophysiology of severe rotavirus infections may also assist drug discovery and development strategies.

To this end there have been considerable efforts over the past 2 decades to identify the role of host-rotavirus interactions in rotavirus pathogenesis. In particular, many efforts have focused on how rotaviruses usurp host cell innate immune responses and the ubiquitous

network of pattern recognition receptors (PRR). Rotaviruses are capable of suppressing interferon (IFN) responses during the early stages of infection.^{5–8} Indeed, prophylactic administration of IFN restricts rotavirus replication both *in vitro* and *in vivo*.^{9–11} Previous investigations have demonstrated that rotavirus infection does not result in PRR-mediated activation of IFN β suggesting that viral-centric mechanisms exist to counteract these responses.^{5,7,12–13} The rotavirus nonstructural protein NSP1 mediates the degradation of multiple interferon regulatory factor (IRF) members including IRF3, IRF5 and IRF7.^{5–6,8} Further, it has also been suggested that NSP1 inhibits the nuclear translocation of the transcription factor signal transducer and activator of transcription 1 (STAT1).¹⁴ Recent investigations have also demonstrated that NSP1 may also downregulate innate immune responses through direct interactions with PRRs as NSP1 can downregulate retinoic acid-inducible gene 1 (RIG-I)-like receptors.¹⁵ In addition, there has been concerted efforts in the investigation of rotavirus-mediated regulation of host cell protein translation. It has been proposed that NSP3 modifies the intracellular localization of polyA-binding protein (PABP) by impairing its interaction with eIF4GI resulting in repression of host translation processes and accentuation of viral translation.^{16–19} Interestingly, recent work by Halasz et al. have demonstrated that rotavirus binding/entry and replication are increased via the induction of $\alpha 2\beta 1$ and $\beta 2$ integrin expression through a phosphatidylinositol 3-kinase (PI3K)-dependent mechanism.²⁰

In this issue of *Virulence*, Yin et al. have provided compelling evidence for a role of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) signaling pathway in productive

CONTACT Jason Kindrachuk  Jason.Kindrachuk@umanitoba.ca  Medical Microbiology & Infectious Diseases, University of Manitoba, 745 Bannatyne Avenue, Room 523, Winnipeg MB R3E 0J9, Canada.

Comment on: Yin Y, et al. PI3K-Akt-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. *Virulence* 2017; [Advance online publication]. PMID:28475412; <https://doi.org/10.1080/21505594.2017.1326443>

© 2018 The Author. Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

rotavirus infection and have identified downstream signaling intermediates that may represent novel anti-rotavirus therapeutic targets.²¹ Here, the authors used *in vitro* cell culture models of rotavirus infection (simian rotavirus strain SA11) using traditional 2D cell culture (immortalized colonic epithelial cells Caco2), 3D human primary intestinal organoids and pharmacologic inhibitors of the PI3K/Akt/mTOR pathway. Prophylactic treatment of immortalized cells and primary organoids with LY294002, a potent inhibitor of PI3K, inhibited total viral RNA and infectious virus particle production. Although these results suggest that PI3K could be an important target for future drug development considerations, the authors further assessed the roles of additional PI3K/Akt/mTOR signaling pathway intermediates in rotavirus infections. Inhibition of mTOR by shRNA or nanomolar concentrations of rapamycin (Sirolimus, Rapamune), a licensed mTOR inhibitor administered for the prevention of organ transplant rejection and lymphangioleiomyomatosis,²² resulted in significantly reduced rotavirus infection. These rapamycin-mediated inhibitory effects were retained following infection with 5 patient-derived rotavirus strains highlighting the broad importance of mTOR to productive rotavirus infection. Treatment with BEZ235, a dual PI3K/mTOR inhibitor, also inhibited rotavirus infection in both primary and immortalized cells. These observations build on previous investigations by Bagchi et al. regarding the importance of the PI3K/Akt/mTOR signaling pathway to rotavirus infection.²³⁻²⁴ Bagchi and colleagues demonstrated that rotavirus A5-13 infection results in activation of the PI3K/Akt signaling pathway through a nonstructural protein 1 (NSP1)-dependent mechanism. Yin et al. provide further confirmation of this phenomenon and provide novel information regarding downstream intermediates within the signaling pathway that are critical for productive rotavirus infections. Modulation of the PI3K/Akt/mTOR signaling pathway during productive infection has been demonstrated to be critical broad range of viruses that impact global health. A diverse range of viral families, including *Filoviridae* (Ebola virus),²⁵ *Coronaviridae* (Middle East respiratory syndrome coronavirus),²⁶ *Poxviridae* (monkeypox virus, cowpox virus, vaccinia virus),²⁷⁻²⁸ *Arenaviridae* (lymphocytic choriomeningitis virus)²⁹ and *Picornaviridae* (coxsackievirus)³⁰ require the activation of this pathway for productive infection.

Prior investigations have demonstrated that the induction of autophagy may represent an early defense mechanism within infected cells during viral infections. It is postulated that the induction of autophagy allows host cells to neutralize an invading pathogen early in the infectious cycle before the activation of apoptotic mechanisms within the infected cells.³¹ Multiple viruses, including human cytomegalovirus,³¹ hepatitis B virus-x³² and chikungunya virus,³² have been shown to induce autophagy in infected

cells. Recently, Wu et al. have demonstrated that rotavirus infection resulted in autophagy induction in the intestines of gnotobiotic pigs.³³ Yin and colleagues have provided accompanying mechanistic data for rotavirus-induced autophagy. The authors demonstrated that silencing of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) resulted in a significant reduction in rotavirus infection as demonstrated by 4E-BP1 knockdown (immortalized cells) or deletion (4E-BP1 knockout mouse embryonic fibroblasts, MEF). Rapamycin treatment had no effect on rotavirus infection under these conditions. In contrast, rapamycin treatment inhibited rotavirus infection following reconstitution of 4E-BP1 in these cells. Building on these observations, Yin et al. demonstrated that knockdown of 1A/1B-light chain LC3-II, a microtubule-associated autophagosomal marker, and Beclin-1, which is involved in the early induction of autophagy.

Yin and colleagues have provided clear evidence for a central role of the PI3K/Akt/mTOR signaling pathway in rotavirus pathogenesis. Further, modulation of this pathway through selective inhibition of pathway intermediates results in inhibition of viral replication through a 4EB-P1-dependent induction of autophagy. Intriguingly, the authors' investigation suggests that licensed kinase inhibitors targeting the PI3K/Akt/mTOR pathway could potentially be repurposed as an alternative therapeutic strategy for combating rotavirus enteritis. The design and development of novel therapeutics, including anti-infectives, is increasingly impaired by the associated time and costs of development for moving novel therapeutics from pre-clinical phases to market. Repurposing of licensed therapeutics for alternative malignancies, including infectious diseases, is an enticing alternative to these impediments with recent support of this strategy from the National Institutes of Health Center for Advancing Translational Sciences.³⁴ Thus, repurposing of licensed kinase inhibitors as novel anti-infective agents appears a logical approach. As of November, 2016, 31 kinase inhibitors have obtained US Food and Drug Administration (FDA) licensure and there are continually increasing numbers in various clinical and pre-clinical stages of development.³⁵ In support of this, the administration of miltefosine (an Akt inhibitor) has been granted approval for use as an antileishmanial agent.³⁶ Our own investigations have demonstrated that pharmacologic inhibition of the PI3K/Akt/mTOR signaling pathway resulted in increased survival in a lethal model of Ebola virus infection in mice²⁵ and that inhibition of mTOR by rapamycin or everolimus inhibited Middle East respiratory syndrome coronavirus infection *in vitro*.²⁶ Yin et al. provide compelling evidence for future *in vivo* efficacy studies of kinase inhibitors in rotavirus infection models. From a broader perspective, these

results provide further justification for detailed investigations of the efficacy of selective inhibitors targeting the PI3K/Akt/mTOR signaling pathway as novel antiviral therapeutics for viruses that impact global human and/or livestock health.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

References

- [1] Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. *Emerg Infect Dis.* 2003;9(5):565-72. <https://doi.org/10.3201/eid0905.020562>. PMID:12737740
- [2] Centers for Disease, C. Prevention. Rotavirus surveillance—worldwide, 2001–2008. *MMWR Morb Mortal Wkly Rep.* 2008;57(46):1255-7. PMID:19023263
- [3] O’Ryan ML, Hermosilla G, Osorio G. Rotavirus vaccines for the developing world. *Curr Opin Infect Dis.* 2009;22(5):483-9. <https://doi.org/10.1097/QCO.0b013e32833040a9>. PMID:19623063
- [4] Patton JT. Rotavirus diversity and evolution in the post-vaccine world. *Discov Med.* 2012;13(68):85-97. PMID:22284787
- [5] Barro M, Patton JT. Rotavirus nonstructural protein 1 subverts innate immune response by inducing degradation of IFN regulatory factor 3. *Proc Natl Acad Sci U S A.* 2005;102(11):4114-9. <https://doi.org/10.1073/pnas.0408376102>. PMID:1541273
- [6] Barro M, Patton JT. Rotavirus NSP1 inhibits expression of type I interferon by antagonizing the function of interferon regulatory factors IRF3, IRF5, and IRF7. *J Virol.* 2007;81(9):4473-81. <https://doi.org/10.1128/JVI.02498-06>. PMID:17301153
- [7] Feng N, Sen A, Nguyen H, Vo P, Hoshino Y, Deal EM, Greenberg HB. Variation in antagonism of the interferon response to rotavirus NSP1 results in differential infectivity in mouse embryonic fibroblasts. *J Virol.* 2009;83(14):6987-94. <https://doi.org/10.1128/JVI.00585-09>. PMID:9420080
- [8] Graff JW, Mitzel DN, Weisend CM, Flenniken ML, Hardy ME. Interferon regulatory factor 3 is a cellular partner of rotavirus NSP1. *J Virol.* 2002;76(18):9545-50. <https://doi.org/10.1128/JVI.76.18.9545-9550.2002>. PMID:12186937
- [9] Dagenais L, Pastoret PP, Van den Broecke C, Werenne J. Susceptibility of bovine rotavirus to interferon. *Brief report. Arch Virol.* 1981;70(4):377-9. <https://doi.org/10.1007/BF01320253>. PMID:6173029
- [10] Schwers A, Vanden Broecke C, Maenhoudt M, Beduin JM, Werenne J, Pastoret PP. Experimental rotavirus diarrhoea in colostrum-deprived newborn calves: Assay of treatment by administration of bacterially produced human interferon (Hu-IFN alpha 2). *Ann Rech Vet.* 1985;16(3):213-8. PMID:4062197
- [11] Lecce JG, Cummins JM, Richards AB. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. *Mol Biother.* 1990;2(4):211-6. PMID:1963065
- [12] Sen A, Pruijssers AJ, Dermody TS, Garcia-Sastre A, Greenberg HB. The early interferon response to rotavirus is regulated by PKR and depends on MAVS/IPS-1, RIG-I, MDA-5, and IRF3. *J Virol.* 2011;85(8):3717-32. <https://doi.org/10.1128/JVI.02634-10>. PMID:21307186
- [13] Arnold MM, Patton JT. Diversity of interferon antagonist activities mediated by NSP1 proteins of different rotavirus strains. *J Virol.* 2011;85(5):1970-9. <https://doi.org/10.1128/JVI.01801-10>. PMID:21177809
- [14] Holloway G, Truong TT, Coulson BS. Rotavirus antagonizes cellular antiviral responses by inhibiting the nuclear accumulation of STAT1, STAT2, and NF-kappaB. *J Virol.* 2009;83(10):4942-51. <https://doi.org/10.1128/JVI.01450-08>. PMID:19244315
- [15] Qin L, Ren L, Zhou Z, Lei X, Chen L, Xue Q, Liu X, Wang J, Hung T. Rotavirus nonstructural protein 1 antagonizes innate immune response by interacting with retinoic acid inducible gene I. *J Virol.* 2011;85:526. <https://doi.org/10.1186/1743-422X-8-526>. PMID:22152002
- [16] Montero H, Arias CF, Lopez S. Rotavirus Nonstructural Protein NSP3 is not required for viral protein synthesis. *J Virol.* 2006;80(18):9031-8. <https://doi.org/10.1128/JVI.00437-06>. PMID:16940515
- [17] Harb M, Becker MM, Vitour D, Baron CH, Vende P, Brown SC, Bolte S, Arold ST, Poncet D. Nuclear localization of cytoplasmic poly(A)-binding protein upon rotavirus infection involves the interaction of NSP3 with eIF4G and RoXaN. *J Virol.* 2008;82(22):11283-93. <https://doi.org/10.1128/JVI.00872-08>. PMID:18799579
- [18] Vitour D, Lindenbaum P, Vende P, Becker MM, Poncet D. RoXaN, a novel cellular protein containing TPR, LD, and zinc finger motifs, forms a ternary complex with eukaryotic initiation factor 4G and rotavirus NSP3. *J Virol.* 2004;78(8):3851-62. <https://doi.org/10.1128/JVI.78.8.3851-3862.2004>. PMID:15047801
- [19] Lopez S, Arias CF. Rotavirus-host cell interactions: An arms race. *Curr Opin Virol.* 2012;2(4):389-98. <https://doi.org/10.1016/j.coviro.2012.05.001>. PMID:22658208
- [20] Halasz P, Holloway G, Turner SJ, Coulson BS. Rotavirus replication in intestinal cells differentially regulates integrin expression by a phosphatidylinositol 3-kinase-dependent pathway, resulting in increased cell adhesion and virus yield. *J Virol.* 2008;82(1):148-60. <https://doi.org/10.1128/JVI.01980-07>. PMID:17942548
- [21] Yin Y, Dang W, Zhou X, Xu L, Wang W, Cao W, Chen S, Su J, Cai X, Xiao S, Peppelenbosch MP, Pan Q. PI3K-Akt-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. *Virulence.* 2017;1-16. <https://doi.org/10.1080/21505594.2017.1326443>. PMID:28475412
- [22] Administration, U S F D, FDA approves Rapamune to treat LAM, a very rare lung disease. 2015.
- [23] Bagchi P, Dutta D, Chattopadhyay S, Mukherjee A, Halder UC, Sarkar S, Kobayashi N, Komoto F, Taniguchi K, Chawla-Sarkar M. Rotavirus nonstructural protein 1 suppresses virus-induced cellular apoptosis to facilitate viral growth by activating the cell survival pathways during early stages of infection. *J Virol.* 2010;84(13):6834-45. <https://doi.org/10.1128/JVI.00225-10>. PMID:20392855
- [24] Bagchi P, Nandi S, Nayak MK, Chawla-Sarkar M. Molecular mechanism behind rotavirus NSP1-mediated PI3

- kinase activation: Interaction between NSP1 and the p85 subunit of PI3 kinase. *J Virol.* 2013;87(4):2358-62. <https://doi.org/10.1128/JVI.02479-12>. PMID:23221569
- [25] Kindrachuk J, Wahl-Jensen V, Safronetz D, Trost B, Hoenen T, Arsenault R, Feldmann F, Traynor D, Postnikova E, Kusalik A, Napper S, Blaney JE, Feldmann H, Jahrling PB. Ebola virus modulates transforming growth factor beta signaling and cellular markers of mesenchyme-like transition in hepatocytes. *J Virol.* 2014;88(17):9877-92. <https://doi.org/10.1128/JVI.01410-14>. PMID:24942569
- [26] Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. *Antimicrob Agents Chemother.* 2015;59(2):1088-99. <https://doi.org/10.1128/AAC.03659-14>. PMID:25487801
- [27] Kindrachuk J, Arsenault R, Kusalik A, Kindrachuk KN, Trost B, Napper F, Jahrling P. B, Blaney JE. Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus. *Mol Cell Proteomics.* 2012;11(6):M111 015701. <https://doi.org/10.1074/mcp.M111.015701>. PMID:22205724
- [28] Soares JA, Leite FG, Andrade LG, Torres AA, De Sousa LP, Barcelos LS, Teixeira MM, Ferreira PC, Kroon EG, Souto-Padron T, Bonjardim CA. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication. *J Virol.* 2009;83(13):6883-99. <https://doi.org/10.1128/JVI.00245-09>. PMID:19386722
- [29] Urata S, Ngo N, de la Torre JC. The PI3K/Akt pathway contributes to arenavirus budding. *J Virol.* 2012;86(8):4578-85. <https://doi.org/10.1128/JVI.06604-11>. PMID:22345463
- [30] Esfandiarei M, Luo H, Yanagawa B, Suarez A, Dabiri D, Zhang J, McManus BM. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. *J Virol.* 2004;78(8):4289-98. <https://doi.org/10.1128/JVI.78.8.4289-4298.2004>. PMID:15047842
- [31] McFarlane S, Aitken J, Sutherland JS, Nicholl MJ, Preston VG, Preston CM. Early induction of autophagy in human fibroblasts after infection with human cytomegalovirus or herpes simplex virus 1. *J Virol.* 2011;85(9):4212-21. <https://doi.org/10.1128/JVI.02435-10>. PMID:21325419
- [32] Wang P, Guo QS, Wang ZW, Qian HX. HBx induces HepG-2 cells autophagy through PI3K/Akt-mTOR pathway. *Mol Cell Biochem.* 2013;372(1-2):161-8. <https://doi.org/10.1007/s11010-012-1457-x>. PMID:23001846
- [33] Wu S, Yuan L, Zhang Y, Liu F, Li G, Wen K, Kocher J, Yang X, Sun J. Probiotic *Lactobacillus rhamnosus* GG mono-association suppresses human rotavirus-induced autophagy in the gnotobiotic piglet intestine. *Gut Pathog.* 2013;5(1);22. <https://doi.org/10.1186/1757-4749-5-22>. PMID:23924832
- [34] Allison M. NCATS launches drug repurposing program. *Nat Biotechnol.* 2012;30(7):571-2. <https://doi.org/10.1038/nbt0712-571a>. PMID:22781662
- [35] Zhang J, Salminen A, Yang X, Luo Y, Wu Q, White M, Greenhaw J, Ren L, Bryant M, Salminen W, Papoian T, Mattes W, Shi Q. Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria. *Arch Toxicol.* 2017;91(8):2921-2938; PMID:28032146; <https://doi.org/10.1007/s00204-016-1918-1>
- [36] Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. *J Antimicrob Chemother.* 2012;67(11):2576-97. <https://doi.org/10.1093/jac/dks275>. PMID:22833634